H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) from $120 to $100, while maintaining a Buy rating on the shares.

The rating follows the company’s fiscal Q4 2025 earnings reported on February 25. Soleno posted quarterly revenue of $91.73 million, surpassing estimates by $3.18 million. The EPS of $0.8 also topped the consensus by $0.09. The revenue was notable as it accounts for less than nine months of commercial sales from the early commercial adoption of VYKAT XR.

​The analyst said in a research note that he sees a strong commercial outlook for the company. He expects the company’s VYKAT XR to capture 20% market share in the total Prader-Willi syndrome market. This is backed by 859 active patients on VYKAT XR treatment at the end of Q4 2025, up from 764 in Q3.

​Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases, including Prader-Willi Syndrome.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.